ProChon Biotech Ltd.
This article was originally published in Start Up
Executive Summary
Prochon Biotech believes it has found a key receptor regulating bone growth, and hopes to develop new drugs for bone growth disorders, with an initial focus on achondroplasia, the most common form of human dwarfism.
You may also be interested in...
TiGenix NV
Belgian start-up TiGenix NV's cartilage repair treatment ChondroCelect may overcome a key hurdle faced by most existing therapies, by selecting in advance of implantation only those cartilage cells least likely to mineralize.
Promised Land for Biotechnology
Israel is the hottest single country for high-tech start-ups in general, but advocates of life sciences say that additional funding specifically for biotechnology is needed. Without a strong pharmaceutical industry, Israel lacks the infrastructure necessary to nurture start-ups, for example, experienced executives to run companies.
Women's Health: Too early or Too Late?
As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.